drugset

drugset / Trial / NCT06403436

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

NCT06403436 ↗

Phase 1 Completed 45 enrolled TOLREMO therapeutics AG

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.

Timeline

Start: 2023-11-07
Primary completion: 2026-06-30
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TT125-802	Unknown	—	Oral

Indications